SIRP alphaV2

SIRP alphaV2

SIRP alphaV2 Molekülinformation

Molecule Name
Signal-regulatory protein alpha
Molekülalias
SHPS1,SIRPA,CD172A,BIT,MFR,MYD1,P84,PTPNS1
Drug Development Progress
Anzahl der klinischen Arzneimittel19
Anzahl der inverkehr gebrachten Arzneimittel2
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
SHPS-1,Macrophage fusion receptor,Brain Ig-like molecule with tyrosine-based activation motifs,MFR,Signal-regulatory protein alpha-1,Signal-regulatory protein alpha-2,CD172a,MyD-1 antigen,Sirp-alpha-3,MYD1,SIRPA,Signal Regulatory Protein Alpha,CD172 Antigen-Like Family Member A,Inhibitory Receptor SHPS-1,PTPNS1,SHPS1,SIRP,P84,Brain-Immunoglobulin-Like Molecule With Tyrosine-Based Activation Motifs,Protein Tyrosine Phosphatase, Non-Receptor Type Substrate 1,Tyrosine-Protein Phosphatase Non-Receptor Type Substrate 1,Tyrosine Phosphatase SHP Substrate 1,Signal-Regulatory Protein Alpha-3,Signal-Regulatory Protein Alpha,SHP Substrate 1,CD172a Antigen,Sirp-Alpha-1,Sirp-Alpha-2,MYD-1,Bit,SIRPalpha,SIRPalpha2
Molekülhintergrund
Tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS1) is also known as CD172 antigen-like family member A (CD172a), Macrophage fusion receptor, MyD-1 antigen, Signal-regulatory protein alpha (SIRPA or SIRP alpha) or p84, is a member of the SIRP family, and also belongs to the immunoglobulin superfamily. SIRP alpha is Ubiquitous and highly expressed in brain. SIRPA / CD172a is immunoglobulin-like cell surface receptor for CD47 and acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. SIRPA / SHPS-1 supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment and may play a key role in intracellular signaling during synaptogenesis and in synaptic function By similarity. SIRPA / MyD1 involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin and mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells.

SIRP alphaV2 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
IpsoprubartELA-026Phase 3 ClinicalElectra Therapeutics Inc
Lymphohistiocytosis, Hemophagocytic; Neoplasms
Details
LM-101LM-101Phase 2 ClinicalLaNova Medicines Ltd
Hematologic Neoplasms; Leukemia; Neoplasms; Solid tumours
Details
HX-044HX044; HX-044Phase 2 ClinicalHanx Biopharmaceuticals Pty Ltd
Lymphoma; Solid tumours
Details
BRB-002BRB-002Phase 2 ClinicalBitterroot Bio Inc
Atherosclerosis; Cardiovascular Diseases; Vasculitis
Details
BI-770371BI-770371Phase 2 ClinicalOse Immunotherapeutics
Carcinoma, Non-Small-Cell Lung; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
IBC-0966IBC-0966Phase 2 Clinical
Neoplasms
Details
HX-009HX-009; HX009-II-02Phase 2 ClinicalWaterstone Hanxbio Pty Ltd
Bile Duct Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Lymphoma; Melanoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
BI-765063OSE-172; BI-765063; Effi-DEMPhase 1 ClinicalEffimune
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
ADU-1805ADU-1805Phase 1 ClinicalAduro Biotech Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Solid tumours
Details
Q-1801Q-1801; Q 1801Phase 1 ClinicalQure Biotechnology (Shanghai) Co Ltd
Solid tumours
Details
Recombinant humanized IgG4 anti-SIRPα antibody(Daiichi Sankyo)DS-1103aPhase 1 ClinicalDaiichi Sankyo Co Ltd
Breast Neoplasms; Solid tumours
Details
JY-47JY47; JY-47Phase 1 ClinicalHangzhou Jiuyuan Gene Biomedical Co Ltd
Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours
Details
BYON-4228BYON-4228Phase 1 ClinicalSanquin Blood Supply Foundation
Lymphoma; Solid tumours
Details
BSI-082BSI-082Phase 1 ClinicalBiosion Inc
Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours
Details
BR-105BR-105; BR105Phase 1 ClinicalHisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd
Lymphoma, Large B-Cell, Diffuse; Neoplasms
Details
[89Zr]Zr- BI-765063(Boehringer Ingelheim)Phase 1 ClinicalBoehringer Ingelheim Corp
Carcinoma, Non-Small-Cell Lung; Melanoma; Squamous Cell Carcinoma of Head and Neck
Details
TQB-2928TQB-2928Phase 1 ClinicalJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Carcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Solid tumours
Details
BI-765080Phase 1 ClinicalC.H. Boehringer Sohn Ag & Co. Kg
Details
ES-004ES-004; ES 004-N4; ES 004-B4Phase 1 ClinicalElpiscience (Shanghai) Biopharma Ltd
Neoplasms; Solid tumours
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Relugolix/Estradiol/Norethindrone AcetateE2/NETAApprovedMyovant SciencesMYFEMBREE, RYEQOUnited StatesMenorrhagia; LeiomyomaSumitomo Pharma America Inc, Myovant Sciences2021-05-26
Endometriosis; Leiomyoma; Menorrhagia; Pain; Uterine Neoplasms
Details
Elagolix/estradiol/norethindrone acetateApprovedAbbvie IncOriahnnUnited StatesMenorrhagiaAbbvie Inc2020-05-29
Menorrhagia
Details